Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase by Eslami, Seyyed Majid et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2016-12-31 
Anticonvulsive Effects of Licofelone on Status Epilepticus 
Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible 
Nitric Oxide Synthase 
Seyyed Majid Eslami 
Tehran University of Medical Sciences 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Nervous System Diseases Commons, Neurology Commons, and the Neuroscience and 
Neurobiology Commons 
Repository Citation 
Eslami SM, Moradi MM, Ghasemi M, Dehpour AR. (2016). Anticonvulsive Effects of Licofelone on Status 
Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase. Open 
Access Articles. https://doi.org/10.14581/jer.16011. Retrieved from https://escholarship.umassmed.edu/
oapubs/3012 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Original Article
Journal of Epilepsy Research
pISSN 2233-6249 / eISSN 2233-6257
Anticonvulsive Effects of Licofelone on Status Epilepticus 
Induced by Lithium-pilocarpine in Wistar Rats: a Role for 
Inducible Nitric Oxide Synthase
Seyyed Majid Eslami1,2, Mohammad Mobin Moradi1,2, Mehdi Ghasemi3, Ahmad Reza Dehpour1,2
1Experimental Medicine Research Center, 2Department of Pharmacology, School of Medicine, Tehran University of Medical 
Sciences, Tehran, Iran, 3Department of Neurology, University of Massachusetts Medical Center, Worcester, MA, USA
Received August 16, 2016
Accepted October 15, 2016
Corresponding author: Ahmad Reza Dehpour
Department of Pharmacology, School of 
Medicine, Tehran University of Medical 
Sciences, Tehran, Iran
Tel. +98 21 8897 3652
Fax. +98 21 6640 2569
E-mail; dehpour@yahoo.com
Background and Purpose: Status epilepticus (SE) is a neurological disorder with high prevalence and 
mortality rates, requiring immediate intervention. Licofelone is a cyclooxygenase (COX) and 5-lipoxygenase 
(5-LOX) inhibitor, which its effectiveness to treat osteoarthritis has been approved. Increasing evidence 
suggests an involvement of COX and LOX enzymes in epileptic disorders. Thus, in the present study we 
investigate possible effects of licofelone on prevention and termination of SE. We also evaluated whether the 
nitrergic system could participate in this effect of licofelone.
Methods: We have utilized lithium-pilocarpine model of SE in adult Wistar rats to assess the potential effect of 
licofelone on seizure susceptibility. Licofelone was administered 1 h before pilocarpine. To evaluate probable 
role of nitric oxide (NO) system, L-arginine (60 mg/kg, i.p.), as a NO precursor; L-NAME (15 mg/kg, i.p.), as a 
non-selective nitric oxide synthase (NOS) inhibitor; aminoguanidine (100 mg/kg, i.p.), as an inducible NOS 
(iNOS) inhibitor and 7-nitroindazole (60 mg/kg, i.p.), as a neuronal NOS inhibitor were injected 15 min before 
licofelone. Also, licofelone and diazepam 10 mg/kg were administered 30 minutes after onset of SE.
Results: Pre-treatment with licofelone at the dosage of 10 mg/kg, significantly prevented the onset of SE in all 
subjects (p < 0.001). L-arginine significantly inverted this anticonvulsant effect (p < 0.05). However, L-NAME 
and aminoguanidine, potentiated the anticonvulsant effect of licofelone (p < 0.05, p < 0.01). Licofelone could 
not terminate seizures after onset which was terminated by diazepam. 
Conclusions: Our findings showed that anticonvulsive effects of licofelone on SE could be mediated by iNOS. 
Also, we suggest that COX/5-LOX activation is possibly required in the initial stage of onset but SE recruits 
extra excitatory pathways with prolongation. (2016;6:53-60)
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Introduction
Status epilepticus (SE), a life-threatening emergency condition, is 
a prolonged self-perpetuating seizure which requires prompt inter-
vention to prevent its injury and mortality.1 Benzodiazepines, such as 
diazepam and lorazepam, are recommended as the first choice anti-
epileptic medication to terminate seizure, but unfortunately if SE 
lasts more than 30-40 minutes, it becomes progressively more re-
fractory to these agents.2 Therefore, applying rapid therapies for 
treating SE, enhances neuroprotection and suppresses the long-term 
sequels such as epileptogenesis, neuronal damage and cognitive 
deficits.3
Licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3,dihy-
dro-1H-pyrrolizine-5-yl]-acetic acid; previously named ML3000) is a 
substrate analogue of arachidonic acid which inhibits cyclo-
oxygenase type 1 and 2 (COX1 and COX2) and 5-lipoxygenase 
(5-LOX), decreasing prostaglandins and leukotrienes production.4 
Licofelone inhibits these enzymes at the equal concentration.5 
Licofelone was developed in order to find compounds with anti-in-
flammatory activity to obviate the gastrointestinal side-effects re-
lated to non-steroidal anti-inflammatory drugs  and its safety profile 
compared to these agents has been authenticated in healthy 
individuals.6 Recent experimental studies have shown that licofelone 
exerts anti-inflammatory properties,7 anti-asthmatic8 and neuro-
protective effects in the central nervous system.9 Licofelone can also 
modulate neuroinflammation and diminish mechanical hypersen-
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sitivity.10 Anticancer effects of this agent in lung,11 colon and small in-
testine12 have been proved. 
It is well established that prostaglandins and leukotrienes possess 
regulatory effect in the pathophysiology of neurological disorders.13 
For instance, potential therapeutic effects of licofelone on neuro-
degeneration and cognitive impairment in animal models of 
Alzheimer’s disease has been reported.14 Licofelone also exerted an-
ticonvulsive effects in some animal models of seizure such as penty-
lenetetrazol-induced seizures in mice.15 Celecoxib, a selective COX-2 
inhibitor, could attenuate neuronal death in the hippocampus.16 In 
another study, COX-2 inhibition ameliorated brain injury and oxida-
tive stress in kainic acid model of SE.17 However, the possible anti-
convulsive effects of licofelone on SE has not been yet investigated.
Among the proposed mechanisms for protective effects of COX 
and LOX inhibitors in the central nervous system (CNS), nitric oxide 
(NO) pathways has been an interest.18 Nitric oxide synthases (NOSs) 
are the group of enzymes, synthesizing NO from L-arginine (L-Arg). 
Depending on the source of NO, seizure models and involving neuro-
transmitter systems, NO represents either proconvulsive or anti-
convulsive effects.15,19 In respect of remarkable role of COX and LOX 
enzymes with NO signaling pathways in CNS disorders, we aimed to 
investigate whether licofelone as a dual COX/LOX inhibitor prevent 
or terminate SE induced by lithium-pilocarpine model in rat and ex-
amine which isoform of NOS could potentially mediate this effect.
Methods
Chemicals
In our study following drugs were used: L-arginine (L-Arg), a NO 
precursor; L-NG-Nitroarginine methyl ester (L-NAME), a non-specific 
NOS inhibitor; aminoguanidine (AG), a specific iNOS inhibitor and 
7-Nitroindazole (7-NI), a specific nNOS inhibitor; pilocarpine and 
lithium chloride (Sigma, St Louis, MO, USA). Licofelone ([2,2 di-
methyl-6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H pyrrazoline-5-yl] 
acetic acid) was a dedicated as a gift from Tofigh daru (Tehran, Iran); 
Scopolamine methyl bromide, a cholinergic muscarinic antagonist 
from Osvah.
Licofelone was freshly dissolved in slightly alkaline water and 7-NI 
in a 1% aqueous solution of DMSO then followed by sonication. 
Other drugs were dissolved in normal saline solution (0.9%). 
Solutions and suspensions of drugs were always prepared in the day 
of experiment. On the basis of our previous study, dosages and time 
of administrations were chosen.15 
Animals
Male adult Wistar rats weighing 200-250 g were selected from 
our center of breeding facilities. The animals were kept in a standard 
temperature-controlled (22 ± 3°C) environment under a 12-h 
light/12-h dark cycle schedule. They had free accessibility to tap wa-
ter and food except for experimental procedure. Each group con-
sisted of 8 animals. All animal maintenance and procedures were es-
tablished in agreement with institutional guidelines for animal care 
and use published by national institutes of health and with the ap-
proval of the Ethics Committee on Animal Experiments of Tehran 
University of Medical Sciences and all efforts were made to minimize 
suffering of the animals.
Induction of SE by lithium-pilocarpine
Animals were injected lithium chloride (127 mg/kg, i.p.). After 20 
hours SE was induced with intraperitoneally injection of pilocarpine 
hydrochloride (60 mg/kg, i.p.). Thirty minutes prior to injection of pi-
locarpine, scopolamine methyl bromide 2 mg/kg i.p was ad-
ministered to limit peripheral side effects of pilocarpine (e.g., saliva-
tion, diarrhea and lacrimation) which was not achieved with the 
standard regimen of scopolamine methyl bromide 1 mg/kg. After pi-
locarpine injection, animals were then closely observed for signs of 
seizure activity, and seizure severity was ranked using Racine’s 
scale20: 1 = seizure consisted of immobility and occasional facial clo-
nus; 2 = head nodding; 3 = bilateral forelimb clonus; 4 = rearing; 5 
= rearing and falling. Generally, “the seizure behavior consists of 
head bobbing with intermittent forelimb and hind limb clonus, hyper-
extension of tails, loss of posture, falling back, and myoclonic jerks, 
whereas SE is a condition where these recurrent generalized seizures 
last for more than 30 minutes in the animals”.21 In consistent with 
previous studies, SE was defined as consecutive seizures with a score 
of 3 or above.20,22-24 In our study, we measured the incidence of SE, 
20 minutes after pilocarpine administration in separate experimental 
groups as explained below.
Experimental procedure
In our first experiment, different doses of licofelone (1, 5 and 10 
mg/kg; i.p.) were injected 1 hours before pilocarpine induced SE. 
Control group was injected with vehicle (slightly alkaline water). In 
the next experiment, we evaluated the effect of the L-arginine as NO 
precursor on the effective dose of licofelone. In this regard, rats were 
administered L-arginine (10, 30 and 60 mg/kg) 15 min before licofe-
lone (5 mg/kg) or 75 min before SE induction by pilocarpine. To ex-
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Figure 1. Effect of acute administration of licofelone (1, 5 and 10 mg/kg) on 
lithium-pilocarpine induced SE. Licofelone was administered 1 h before 
pilocarpine. One tailed Z-test explain a significant effect for licofelone 10 
mg/kg compare with vehicle control group. At the dose of 10 mg/kg the 
Z-Score is 4. The p-value is < 0.0001. The result is significant at p < 0.001. Data
are expressed as the percentages of rats that experienced SE. Each group 
comprised of 8 rats. *p < 0.001 compared with vehicle control group. 
Figure 2. Effect of pre-treatment with different doses of the NO precursor 
L-arginine (10, 30 and 60 mg/kg) on the anticonvulsive trait of licofelone (5
mg/kg) in lithium-pilocarpine induced SE. L-arginine was injected 15 
minutes prior to licofelone. One tailed Z-test explains that L-arginine (60 
mg/kg) reversed the effect of licofelone. In experimental group of 60 mg/kg
Z-Score is 1.9215. The p-value is 0.0273. The result is significant at p < 0.05.
Data are expressed as the percentages of rats that experienced SE. Each 
group comprised of 8 rats. *p < 0.05 compared with the licofelone (5 
mg/kg) treated group. NO, nitric oxide; SE, status epilepticus.
amine the effect of NO inhibition on seizure susceptibility, rats were 
administered the non-specific NOS inhibitor L-NAME at doses of (1, 5 
and 15 mg/kg) 75 min before pilocarpine. To evaluate which isoform 
of NO could specifically mediate this process, 7-NI (60 mg/kg) as a 
neuronal NOS inhibitor and AG (100 mg/kg) as an inducible NOS in-
hibitor were used 75 min prior to pilocarpine administration. To eval-
uate whether licofelone could terminate seizure, we injected licofe-
lone (10 mg/kg) or diazepam (10 mg/kg, as gold standard) 30 mi-
nute after SE.
Statistical analysis
In each experimental group results of seizure incidences are ex-
pressed by population proportions of SE occurrence. Data were ana-
lyzed by one-way z-score test. In all experiments, p value 0.05 was 
regarded as significant.
Results
Effect of different doses of licofelone on 
lithium-pilocarpine induced SE
Fig. 1 elucidates the effect of acute administration of licofelone 
(1, 5 and 10 mg/kg) on lithium-pilocarpine induced SE. Licofelone 
was injected 1 h before pilocarpine. One tailed Z-test explains a sig-
nificant effect for administration of licofelone (10 mg/kg) [The 
Z-Score was 4 and the p value was <0.0001]. The result is sig-
nificant at p < 0.001 as an anticonvulsant factor compared with ve-
hicle control rats.
Effect of L-arginine pre-treatment in combination 
with licofelone 
Fig. 2 shows the effect of pre-treatment with L-arginine (10, 30 
and 60 mg/kg) on the anticonvulsive dose of licofelone (5 mg/kg, i.p.) 
on lithium-pilocarpine induced SE. L-arginine was injected 15 mi-
nutes prior to licofelone. One tailed Z-test explains that L-arginine 
(60 mg/kg) reduced the anticonvulsive effect of licofelone [The 
Z-Score is 1.9215. The p value was 0.0273. The result was significant 
at p <0.05].
Effects of L-NAME pre-treatment in combination 
with licofelone
Fig. 3 shows the effect of pre-treatment with L-NAME (1, 5 and 15 
mg/kg) on anticonvulsive effects of licofelone (5 mg/kg, i.p.) on lith-
ium-pilocarpine induced SE. L-NAME was injected 15 minutes prior 
to licofelone. One tailed Z-test shows that L-NAME (15 mg/kg) in-
creased the anticonvulsive effect of licofelone (5 mg/kg) [The 
Z-Score was 2.0656. The p value was 0.0194. The result was sig-
nificant at p < 0.05].
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Figure 5. Effect of the neuronal NOS inhibitor 7-NI (60 mg/kg) on the 
anticonvulsive property of licofelone (5 mg/kg) on lithium-pilocarpine 
induced SE. 7-NI was injected 15 minutes prior to licofelone. In the 
administration of 7-NI (60 mg/kg) our data shows that it does not have 
significant involvement on the effect of licofelone. Data are expressed as 
the percentages of rats that experienced SE. Each group comprised of 8 
rats. NOS, nitric oxide synthase; SE, status epilepticus.
Figure 4. Effect of the selective iNOS inhibitor AG (100 mg/kg) on the 
anticonvulsive property of licofelone (5 mg/kg) on lithium-pilocarpine 
induced SE. AG was injected 15 minutes prior to licofelone. One tailed 
Z-test explains that AG (100 mg/kg) increased the anticonvulsive effect of 
licofelone compared with group receiving saline and licofelone (5 mg/kg). 
The Z-Score is 2.6968. The p-value is 0.00347. The result is significant at p
< 0.01. Data are expressed as the percentages of rats that experienced SE. 
Each group comprised of 8 rats. ** p < 0.01 compared with the vehicle 
control group. iNOS, inducible nitric oxide synthase, SE, status epilepticus; 
AG, aminoguanidine.
Figure 3. Effect of the non-specific NOS inhibitor L-NAME at different doses
(1, 5 and 15 mg/kg) on the anticonvulsive property of licofelone (5 mg/kg) 
in lithium-pilocarpine induced SE. L-NAME was injected 15 minutes prior to 
licofelone. One tailed Z-test shows that L-NAME increased the 
anticonvulsive effect of licofelone compared with group receiving saline 
and licofelone (5 mg/kg). At the dose of L-NAME 15 mg/kg Z-Score is 
2.0656. The p-value is 0.0194. The result is significant at p < 0.05. Data are 
expressed as the percentages of rats that experienced SE. Each group 
comprised of 8 rats. *p < 0.05 compared with corresponding licofelone (5 
mg/kg) treated group. NOS, nitric oxide synthase.
Effects of pre-treatment with AG in combination 
with licofelone
Fig. 4 shows the effect of pre-treatment with AG (100 mg/kg) on 
the anticonvulsant trait of licofelone (5 mg/kg) on lithium-pilocarpine 
induced SE. AG was injected 15 minutes prior to licofelone. One 
tailed Z-test explains that AG (100 mg/kg) increased the anti-
convulsant effect of licofelone (5 mg/kg) [The Z-Score is 2.6968. The 
p value was 0.00347. The result was significant at p < 0.01].
Effects of pre-treatment with 7-NI in combination 
with licofelone
Fig. 5 shows the effect of pre-treatment with 7-NI (60 mg/kg) on 
the anticonvulsant trait of licofelone (5 mg/kg, i.p.) on lith-
ium-pilocarpine induced SE. 7-NI was injected 15 minutes prior to 
licofelone. Our data shows that 7-NI did not have significant involve-
ment on the effect of licofelone.
Effects of treatment with Licofelone and diazepam 
after SE
Fig. 6 shows the response of subjects to licofelone and diazepam 
administration 30 minutes after onset of SE. Our Data clarifies that li-
cofelone (10 mg/kg) could not terminate SE which was terminated by 
diazepam (10 mg/kg).
Discussion
In the present study, we demonstrated that licofelone exerted an-
ticonvulsive effects against SE induced by lithium-pilocarpine in male 
Wistar rats in a dose dependent manner. Pre-treatment with the NO 
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Figure 6. Response to administrating of diazepam (10 mg/kg) as a central 
nervous system depressant and licofelone (10 mg/kg) 30 minutes after 
onset of SE that made by lithium-pilocarpine. Experiments shows that 
diazepam (10 mg/kg) terminated SE in all subjects but licofelone (10/mg) 
(that worked properly as prophylactive anticonvulsive agent [Fig. 1]) could 
not terminate SE. Data are expressed as the percentages of rats that 
experienced SE. Each group comprised of 8 rats. SE, status epilepticus.
precursor L-arginine decreased the anticonvulsive effects of licofe-
lone, whereas the non-selective NOS inhibitor L-NAME potentiated 
the protective effects of licofelone. To clarify which isoform of NOS is 
involved in this effect of licofelone, the selective nNOS inhibitor 7-NI 
and the selective iNOS inhibitor AG were injected in combination 
with licofelone. Pre-treatment with 7-NI did not change seizure sus-
ceptibility significantly but co-administration of AG and licofelone ex-
erted anticonvulsive effects. These data suggested that the NO path-
way especially iNOS contributes to the anticonvulsive effects of the 
COX/5-LOX inhibitor licofelone on SE induced by lithium-pilocarpine 
in male Wistar rats. Despite its protective effect as prophylaxis, it 
could not terminate SE, indicating that after onset, COX/5-LOX 
blockage are not enough to terminate SE.
There is evidence that inflammatory processes could participate in 
the pathophysiology of SE. Accordingly, Marchi et al. reported that in 
pilocarpine induced SE, pilocarpine causes acute peripheral in-
flammation mostly through interleukin 1 beta (IL-1β), leading to 
blood-brain barrier (BBB) leakage before the onset of SE25 and in-
creasing BBB permeability may promote entry of cofactors (e. g. K+) 
into the brain leading to pilocarpine-induced SE. More investigation 
revealed that administration of the muscarinic acetylcholine receptor 
antagonist, atropine, blocked the seizure while it is not affected 
when SE is established, representing that activation of muscarinic re-
ceptors are required in the initial phase but recruits noncholinergic 
pathways with prolongation.26 These pathways include excitotoxic 
transmission system including N-methyl-D-aspartate (NMDA) and 
non-NMDA glutamate receptors which open ionic channels per-
meable to calcium (Ca2+).27 During SE, gamma-aminobutyric acid 
(GABA) biosynthesis in substantia nigra fails and there will be a re-
duction in available GABAA postsynaptic receptors.
28 These losses of 
inhibitory neurotransmitter and its receptors are possible etiologies 
to become pharmacoresistance to benzodiazepines.
Recent studies also reported that COX/LOX inhibition could have 
protective effects in CNS disorders via its property to modulate in-
flammation, apoptosis and oxidative stress.29,30 BW755C, a dual 
LOX/COX inhibitor, has also been shown to protect brain damage in 
kainate-induced seizure.31 Cyclooxygenases (COX) are the enzymes 
existing in two types of COX-1 and COX-2, metabolizing arachidonic 
acid to biologically active molecules.32 COX-1 is continually ex-
pressed in most tissue, producing prostaglandins (PGs) at low con-
centration to maintain the physiological functions.33 COX-2 is the in-
ducible form of COX which plays a critical part in inflammation.34 
However, COX-2 is continuously expressed in stomach and kidney 
which is not associated with inflammation.35 Several studies revealed 
the anticonvulsive and neuroprotective effect of selective and 
non-selective COX inhibitors in various models of seizure.36,37 A se-
lective COX-2 inhibitor, celecoxib, and a non-selective COX inhibitor, 
aspirin, could attenuate hippocampal neuronal loss.16,38 Some stud-
ies showed that NO activates COX enzymes39 and mutually it is hy-
pothesized that COX-2 activation causes NO upregulation.40 
However it is proposed  that NO activates COX-1 derived prosta-
glandin while inhibits COX-2 production.41 Interaction between iNOS 
and COX-2 have also been shown to be involved in IL-1β induced ac-
tivation of rat primary hippocampal culture.42
5-LOX is an enzyme that inserts oxygen in arachidonic acid, turn-
ing to leukotrienes, which are potent mediators in inflammatory 
processes. LOX mostly exists in brain tissue and neurons and may 
participate in neurodegeneration.43 5-LOX is upregulated in various 
CNS disorders such as multiple sclerosis, stroke, and Alzheimer's 
disease.44-46 Accordingly, 5-LOX inhibitors have been considered to 
be neuroprotective. Additionally, the end products of 5-LOX, leuko-
trienes, can induce NO synthesis,47 while it has been reported that 
NO-donor compounds inhibits LOX activity.48 Bhujade and col-
leagues reported that a plant extracts inhibited inflammatory media-
tors, COX and 5-LOX through down regulation of iNOS.49
Many molecular signaling pathways are triggered during epilep-
togenesis. Among these proposed mechanisms, activation of the 
AMPA, kainite and NMDA receptors has been reported to play a key 
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role in neuronal excitability in seizures.50 Increment of hippocampal 
nitrite content after SE, suggests a role for NO system in SE.51 
Glutamate release due to NOS activation might be the underlying 
mechanism.52 In one study, median convulsive dose of ciprofloxacin 
was increased by AG and decreased with L-arginine, suggesting that 
elevation of brain glutamate is the consequence of iNOS activation.53 
In consistent with the above evidence, our data also revealed that 
iNOS inhibition could potentiate the anticonvulsive effects of the 
COX/5LOX inhibitor licofelone on SE induced by lithium-pilocarpine. 
These results are in line with previous study that showed the involve-
ment of iNOS in the anticonvulsive effect of licofelone against penty-
lenetetrazol-induced seizures in mice.15 Additionally, previous studies 
have shown that licofelone is able to decrease NO production or de-
crease iNOS activation in cartilage chondrocytes.54,55 It is also shown 
that activation of LOX and COX causes oxidative stress leading to 
apoptosis of GABAergic neurons56; and neuronal damage due to 
seizures is associated with upregulation of iNOS in hippocampus.57 It 
seems that variant models of seizure, source of NO, and other neuro-
transmitter involving during epileptogenesis are the underlying rea-
sons for these differences.
In conclusion, in the present study, we demonstrated that anti-
convulsive effect of licofelone, as a COX/5-LOX inhibitor, on lith-
ium-pilocarpine induced SE in rats, is potentiated by both the non-se-
lective NOS inhibitor L-NAME and the selective iNOS-inhibitor AG, 
representing that NO pathway, especially iNOS, mediates this pro-
tective effect of licofelone.
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